

---

## **Alzheimer's and Parkinson's Diseases: Advances, Concepts and New Challenges**

9th International Conference AD/PD  
Prague, Czech Republic, March 11–15, 2009

### **Abstracts**

---

Guest Editors

*Abraham Fisher, Ness Ziona*

*Israel Hanin, Tucson, Ariz.*

*Roger M. Nitsch, Zürich*

*Manfred Windisch, Graz*

**KARGER**

Basel • Freiburg • Paris • London • New York •  
Bangalore • Bangkok • Singapore • Tokyo • Sydney

S. Karger  
Medical and Scientific Publishers  
Basel • Freiburg • Paris • London  
New York • Bangalore • Bangkok  
Singapore • Tokyo • Sydney

#### Disclaimer

The statements, options and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

#### Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

#### All rights reserved.

No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center (see 'General Information').

© Copyright 2009 by S. Karger AG,  
P.O. Box, CH-4009 Basel (Switzerland)  
ISBN 978-3-8055-9118-8

---

**KARGER**

Fax +41 61 306 12 34  
E-Mail [karger@karger.ch](mailto:karger@karger.ch)  
[www.karger.com](http://www.karger.com)

## Contents

### Preconference Satellite Symposia and EU Sponsored Sessions

**Wednesday, March 11, 2009**

**Thursday, March 12, 2009**

**Friday, March 13, 2009**

**Saturday, March 14, 2009**

**Sunday, March 15, 2009**

**Author Index**

---

# Neuro- degenerative Diseases

## Editors-in-Chief

R.M. Nitsch, Zürich  
C. Hock, Zürich

## Section Editors

### Modeling Neurodegenerative Diseases in vivo

J.-P. Loeffler, Strasbourg  
J.-L. Gonzalez de Aguilar, Strasbourg

### Clinical Drug Trial Section

P. Herrling, Basel  
V. Pogačić Kramp, Basel

## Editorial Board

### Neurobiology

*Molecular Biology*  
K. Beyreuther, Heidelberg  
R. Klein, Martinsried  
M.S. Levine, Los Angeles, Calif.  
B. Martoglio, Basel  
S.S. Sisodia, Chicago, Ill.  
E.E. Wanker, Berlin

*Cell Biology*  
M.F. Beal, New York, N.Y.  
A. Björklund, Lund  
S. Gandy, Philadelphia, Pa.  
M. Goedert, Cambridge  
C. Haass, München  
K. Iqbal, Staten Island, N.Y.  
T. Iwatsubo, Tokyo  
E.H. Koo, San Diego, Calif.  
G. Nikkhah, Freiburg  
N.K. Robakis, New York, N.Y.  
D.J. Selkoe, Boston, Mass.  
G. Thinakaran, Chicago, Ill.  
K. Unsicker, Heidelberg  
B. Wolozin, Maywood, Ill.  
B.A. Yankner, Boston, Mass.

*Animal Models*  
R. Baumeister, Freiburg  
K. Duff, New York, N.Y.  
D.L. Price, Baltimore, Md.  
J. Shen, Boston, Mass.  
O. von Bohlen und Halbach, Heidelberg

*Structural Biology*  
R. Glockshuber, Zürich  
B. Solomon, Tel Aviv  
C. Soto, Galveston, Tex.

### Clinical Research

*Genetics*  
A. Brice, Paris  
J. Hardy, Bethesda, Md.  
L. Lannfelt, Uppsala  
W. Le, Shanghai  
H. Lehrach, Berlin  
S. Lovestone, London  
J. Mallet, Paris

E.I. Rogaev, Moskva  
G.D. Schellenberg, Seattle, Wash.  
C.E. Shaw, London  
A. Singleton, Bethesda, Md.  
P.H. St George-Hyslop, Toronto  
R.E. Tanzi, Boston, Mass.  
C. Van Broeckhoven, Antwerpen

*Neuropathology*  
A. Aguzzi, Zürich  
B. Ghetti, Indianapolis, Ind.  
C.L. Masters, Melbourne  
M.G. Spillantini, Cambridge

*Imaging*  
N.C. Fox, London  
R.S. Frackowiak, London  
A. Villringer, Berlin

*Biological Markers*  
K. Blennow, Mölndal  
T.N. Chase, Washington, D.C.  
J. Ghika, Lausanne  
J.H. Growdon, Boston, Mass.

*Therapy*  
M. Bähr, Göttingen  
S.T. DeKosky, Pittsburgh, Pa.  
J. Dichgans, Tübingen  
B. Dubois, Paris  
W.H. Oertel, Marburg  
M.N. Rossor, London

### Drug Discovery

*Biotechnology*  
P. Aebischer, Lausanne  
D.B. Schenk, San Francisco, Calif.

*Pharmaceuticals*  
K.M. Felsenstein, Spring House, Pa.  
A. Fisher, Ness Ziona  
L.L. Iversen, Oxford  
J.A. Kemp, Hamburg  
M. Miyamoto, Osaka  
H. Möhler, Zürich  
B. Schmidt, Darmstadt  
H. Soreq, Jerusalem  
M. Takeda, Osaka  
M.B.H. Youdim, Haifa

'Neurodegenerative Diseases' is a bimonthly, multi-disciplinary journal for the publication of advances in the understanding of 'Neurodegenerative Diseases', including Alzheimer disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington disease and related neurological and psychiatric disorders. 'Neurodegenerative Diseases' publishes results from basic and clinical scientific research programs designed to better understand the normal functions of genes and proteins involved in 'Neurodegenerative Diseases', to characterize their role in pathogenic disease mechanisms, to model their functions in animals and to explore their roles in the diagnosis, treatment and prevention of 'Neurodegenerative Diseases'. It is our firm belief that successful strategies for novel treatments of 'Neurodegenerative Diseases' will emerge from the intelligent integration of basic neurobiology with clinical sciences. Therefore, 'Neurodegenerative Diseases' will accept high-quality papers from a broad spectrum of scientific research areas ranging from molecular and cell biology to neuroscience, pharmacology, genetics and the clinical sciences.

'Neurodegenerative Diseases' is a peer-reviewed journal that publishes original research in the form of Articles and Brief Communications to 'Neurodegenerative Diseases' as well as Review Articles, Mini Reviews and Commentaries.

## Submission

Only original papers written in English are considered and should be submitted online:

[www.karger.com/ndd](http://www.karger.com/ndd)

Should you experience any problems with your submission, please contact:

[ndd@karger.ch](mailto:ndd@karger.ch)

Editorial Office 'Neurodegenerative Diseases'  
S. Karger AG  
P.O. Box  
CH-4009 Basel (Switzerland)  
Tel. +41 61 306 1357  
Fax +41 61 306 1434

Names, postal and e-mail addresses of four experts in the appropriate area of research should accompany each manuscript. Selected scientist(s) will be invited to act as referee(s). Referees suggested should not be from the same institution as the author and should have expert knowledge of the subject.

Articles should be fully documented reports of original research. They must describe significant and original observations to be critically evaluated and, if necessary, repeated. They do not normally exceed 6 printed pages including all figures, tables and references.

*Brief Communications to Neurodegenerative Diseases* are short reports of original research and are intended to provide a rapid means of reporting new findings of sufficient importance. They do not normally exceed 2 printed pages including an abstract, essential references and not more than 3 tables or figures.

*Review Articles, Mini Reviews and Commentaries* are either invited by the Editors or may be submitted for consideration. Authors who wish to contribute a manuscript to one of these categories should contact the Editor-in-Chief.

## Guidelines for Authors

*Review Articles* describe new developments of interdisciplinary significance and highlight unresolved questions and future directions. They do not generally occupy more than 9 printed pages. Mini Reviews should focus on topics of current interest and not exceed 5 printed pages.

*Commentaries* should offer a more personalized perspective on a topic that will be of interest to the general readership and fill an integral number of printed pages, generally one or two, including one or two small figures. All contributions to these categories will be subjected to editorial review.

*Reports* should comprise title page, Key Words, Abstract, Introduction, Results and Discussion, References, tables, figure legends, and figures – in this order.

## Special Section:

### Modeling Neurodegenerative Diseases in vivo

Editorial policies and guidelines for submission to this new section are as those given for the prime section of 'Neurodegenerative Diseases'.

Diverging from those indications, please submit your paper directly to:

Jean-Philippe Loeffler, PhD  
Tel. +33 390 243 081  
E-Mail [loeffler@neurochem.u-strasbg.fr](mailto:loeffler@neurochem.u-strasbg.fr)

José-Luis Gonzalez de Aguilar, PhD  
Tel. +33 390 243 091  
E-Mail [gonzalez@neurochem.u-strasbg.fr](mailto:gonzalez@neurochem.u-strasbg.fr)

Laboratoire de Signalisations Moléculaires et  
Neurodégénérescence  
INSERM U-692  
Faculté de Médecine  
Université Louis Pasteur  
11, rue Humann  
F-67085 Strasbourg (France)

## Conditions

Only manuscripts that conform to the Guidelines for Authors will be considered and are subject to editorial review.

The manuscript must be accompanied by a cover letter stating that all authors have seen and given their approval for submission of the manuscript to be considered for publication in 'Neurodegenerative Diseases'. Manuscripts are accepted for review with the understanding that persons cited in unpublished work have approved such citations. Authors may provide the names and contact information for three or four suggested reviewers for their papers.

Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication or have not already been published elsewhere. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of 'Neurodegenerative Diseases' and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

The authors agree that their articles will be accompanied, if necessary, by a simplified version written by a scientific writer.

Manuscripts that do not comply with the ethical standards recommended by the Helsinki Declaration will not be accepted.

## Arrangement

*Title page:* The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, and a short title for use as running head.

NB: Authors wishing to preserve the phonetic meaning of diacritics (PubMed reduces diacritics to their root characters) must spell their names accordingly when submitting manuscripts (e.g. Müller should be Mueller).

*Full address:* The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone/fax numbers and e-mail address.

*Key words:* For indexing purposes, a list of 3–10 key words (no abbreviations) in English is needed.

*Abstract:* Each paper needs an abstract of about 200 words, and should be structured as follows:

*Background:* What prompted the study?

*Objective:* What is the purpose of the study?

*Methods:* How was the study carried out?

*Results:* What are the most important findings?

*Conclusion:* What is the most important conclusion? The abstract should not exceed 250 words, and any abbreviations must be explained.

*Footnotes:* Avoid footnotes. When essential, they should be numbered consecutively and typed at the foot of the appropriate page.

*Tables and illustrations:* Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and figure legends should be supplied on a separate sheet. For the reproduction of illustrations, only good drawings and original photographs will be accepted; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, and line drawings one of 800–1,200 dpi.

## Color illustrations

**Online edition:** Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

**Print edition:** Up to 6 color illustrations per page can be integrated within the text at CHF 760.– per page.

*References:* Identify references in the text with Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as 'unpublished data' and not be included in the reference list. The list of references should include only those publications cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in

the text. The surnames of the authors followed by their initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. (Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals. *N Engl J Med* 1997;336:309–315.)

#### Examples

(a) *Papers published in periodicals*: Desai MY, De la Peña-Almaguer E, Mannting F: Abnormal heart rate recovery after exercise: A comparison with known indicators of increased mortality. *Cardiology* 2001;96:38–44.

(b) *Papers published only with DOI numbers*:

Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. *Int Arch Allergy Immunol* DOI: 10.1159/000063858.

(c) *Books*: Matheis G, Moritz A, Scholz M (eds): *Leukocyte Depletion in Cardiac Surgery and Cardiology*. Basel, Karger, 2002.

(d) *Edited books*: Gladish GW, Haponik EF: *Virtual Bronchoscopy*; in Bolliger CT, Mathur PM (eds): *Interventional Bronchoscopy*. *Prog Respir Res*. Basel, Karger, 2000, vol 30, pp 253–266.

Papers that have been submitted but are not yet accepted should not be listed in the bibliography, but can be referred to in the text as unpublished observations. If details of methods are only available in papers that

are ‘in press,’ copies of the papers should be included with the manuscript submitted to ‘Neurodegenerative Diseases’ so that the editorial referees can have adequate information to judge the manuscript.

*Reference Management Software*: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

#### Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at [www.doi.org](http://www.doi.org).

#### Drugs

Generic names should be used in text, tables, and figures. Trade names in upper case may be mentioned in parentheses in the first text reference to the drug but should not appear in titles, figures or tables. The chemical nature of new drugs must be given when known.

#### Abbreviations

When an abbreviation is used in the manuscript, it should be defined in the text the first time it is used. Abbreviations for commonly used substances should be those recommended by the *Journal of Biological Chemistry*. Abbreviations for drugs/chemicals may be used if properly defined with the chemical or generic

name when the abbreviation is first used. Excessive use of abbreviations in the text, however, is strongly discouraged. Most abbreviations are used without punctuation, with no distinction between singular and plural forms.

#### Author's Choice™

With this option the author can choose to make his article freely available online against a one-time fee of CHF 2750.–. This fee is independent of any standard charges for supplementary pages, color images etc. which may apply. More information can be found at [www.karger.com/authors\\_choice](http://www.karger.com/authors_choice).

#### Proofs

Unless otherwise indicated, proofs are sent to the first-named author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer's errors, are charged to the author. No page proofs are supplied.

#### Reprints

Order forms and a price list will be sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

ISSN Print Edition: 1660-2854  
ISSN Online Edition: 1660-2862

Journal Homepage: [www.karger.com/neurodis](http://www.karger.com/neurodis)

**Publication Data:** 'Neurodegenerative Diseases' is published 6 times a year. Volume 6 with 6 issues appears in 2009.

**Copyright:** © 2009 S. Karger AG, Basel (Switzerland). All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.

**Disclaimer:** The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

## General Information

**Subscription Rates:** Subscriptions run for a full calendar year. Prices are given per year.

*Personal subscription:*

Print or Online	Print+Online combined
CHF 398.10	CHF 443.10
EUR 284.40	EUR 316.40
USD 379.20	USD 422.20

**postage and handling** (added to print and print+online)  
CHF 37.80 Europe, CHF 56.70 Overseas  
EUR 27.-  
USD 53.70

*Institutional subscription:*

Print or Online	Print+Online combined
CHF 1327.-	CHF 1460.-
EUR 948.-	EUR 1043.-
USD 1264.00	USD 1390.00

**postage and handling** (added to print and print+online)  
CHF 47.40 Europe, CHF 70.80 Overseas  
EUR 33.60  
USD 67.20

*Airmail surcharge:* CHF 48.- / USD 45.60

**Back Volumes and Single Issues:** Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at [service@karger.ch](mailto:service@karger.ch).

**Bibliographic Indices:** This journal is regularly listed in bibliographic services, including *Current Contents*® and PubMed/MEDLINE.

**Photocopying:** This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for the personal or internal use of specific clients, provided that the stated fee is paid per copy directly to

Copyright Clearance Center Inc.  
222 Rosewood Drive  
Danvers, MA 01923 (USA)

A copy of the first page of the article must accompany payment. Consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. In these cases, specific written permission must be obtained from the copyright owner, S. Karger AG, P.O. Box CH-4009 Basel (Switzerland).

### Subscription Orders:

Orders can be placed at agencies, bookstores, directly with the Publisher

S. Karger AG  
Medical and Scientific Publishers  
P.O. Box  
CH-4009 Basel  
Switzerland  
(for courier services only:  
Allschwilerstrasse 10  
CH-4055 Basel)  
Tel. +41 61 306 11 11  
Fax +41 61 306 12 34  
E-Mail [karger@karger.ch](mailto:karger@karger.ch)  
[www.karger.com](http://www.karger.com)

### Change of Address:

Both old and new address should be sent to the subscription source.

or further Karger offices or representatives:

*France:*  
Librairie Medi-Sciences Sarl  
36, bd de Latour-Maubourg  
75007 Paris  
France  
Tél. +33 (0) 1 45 51 42 58  
Fax +33 (0) 1 45 56 07 80  
E-Mail [librairie@medi-sciences.fr](mailto:librairie@medi-sciences.fr)  
[www.medi-sciences.fr](http://www.medi-sciences.fr)

*Germany:*  
S. Karger GmbH  
Postfach  
79095 Freiburg  
Deutschland  
(Hausadresse: Lörracher Strasse 16A  
79115 Freiburg)  
Tel. +49 761 45 20 70  
Fax +49 761 45 20 714  
E-Post [information@karger.de](mailto:information@karger.de)  
[www.karger.de](http://www.karger.de)

### India, Bangladesh, Sri Lanka:

Panther Publishers Private Ltd.  
33, First Main  
Koramangala First Block  
Bangalore 560 034  
India  
Tel. +91 80 25505 836  
Tel. +91 80 25505 837  
Fax +91 80 25505 981  
E-Mail [panther\\_publishers@vsnl.com](mailto:panther_publishers@vsnl.com)  
[www.pantherpublishers.com](http://www.pantherpublishers.com)

### Japan:

Karger Japan, Inc.  
Yushima S Bld. 3F  
4-2-3, Yushima, Bunkyo-ku  
Tokyo 113-0034  
Japan  
Tel. +81 3 3815 1800  
Fax +81 3 3815 1802  
E-Mail [publisher@karger.jp](mailto:publisher@karger.jp)

### China, Taiwan and Malaysia:

Karger China  
Suite 409, Apollo Building  
1440 Central Yan An Road  
Shanghai 200040  
China  
Tel. +86-21-6133 1861  
Fax +86-21-6133 1862  
E-Mail [karger.ray@gmail.com](mailto:karger.ray@gmail.com)

### South America and Central America:

Cranbury International LLC  
7 Clarendon Ave., Suite 2  
Montpelier, VT 05602  
USA  
Tel. +1 802 223 6565  
Fax +1 802 223 6824  
E-Mail  
[eatkin@cranburyinternational.com](mailto:eatkin@cranburyinternational.com)  
[www.cranburyinternational.com](http://www.cranburyinternational.com)

### United Kingdom, Ireland:

S. Karger AG  
c/o London Liaison Office  
4 Rickett Street  
London SW6 1RU  
United Kingdom  
Tel. +44 (0) 20 7386 0500  
Fax +44 (0) 20 7610 3337  
E-Mail [uk@karger.ch](mailto:uk@karger.ch)

### USA:

S. Karger Publishers, Inc.  
26 West Avon Road  
P.O. Box 529  
Unionville, CT 06085  
USA  
Toll free: +1 800 828 5479  
Tel. +1 860 675-7834  
Fax +1 860 675-7302  
E-Mail [karger@snet.net](mailto:karger@snet.net)